An interventional study of pharmaceutical education in Type 2 Diabetes, Systemic Arterial Hypertension and Medication Adherence, sponsored by Hospital Civil Juan I. Menchaca. Completed at 1 site in Mexico. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-03.
Sponsored by Hospital Civil Juan I. Menchaca · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico — 27 open to participants now, 42 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Mexico.
Among the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico, this one is the 338th largest by enrollment of the 427 interventional ones that give a count, is one of 13 that started in 2019, is one of 43 with no phase, and was the 379th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →27 of the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico are open now. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Mexico, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Mexico, United States, Argentina and 7 more countries
Ages 10–18
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Sites in Mexico
Ages 18+
Eli Lilly and Company · Sites in Mexico, United States, Belgium and 8 more countries
Ages 10–17
AstraZeneca · Sites in Mexico, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
451 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 70 · Phase 3 269 · Phase 4 43
First in 2000; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 442 across the 427 interventional studies, 1,000 across the 23 observational. Of the 384 that completed or were terminated, 240 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 451 have an industry lead sponsor. The 10 most frequent:
Hospital Civil Juan I. Menchaca is the lead sponsor of 5 studies on the registry; none are open to participants now.
Hospital Civil Juan I. Menchaca has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies in Diabetes Mellitus, Type 2 with a site in Mexico that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07628985Phase 3Carnot LaboratoriesBALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | 2027-10 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07401992Hospital Universitario Dr. Jose E. GonzalezEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | 2027-02-28 |
| NCT06069518Coordinación de Investigación en Salud, MexicoContinuous Glucose Monitoring in Patients With Diabetes on Peritoneal Dialysis | 2027-03-31 |
| NCT06163248Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranChrono Nutrition and Insulin Resistance in Diabetes | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 451 studies in Diabetes Mellitus, Type 2 with a site in Mexico, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose. To evaluate the impact of pharmaceutical education in patients with Type 2 Diabetes Mellitus and Systemic Arterial Hypertension on their medication adherence.
Material and research methods. Randomized clinical trial with a control group with a duration of 6 months of follow-up. Patients with a diagnosis of Type 2 Diabetes Mellitus andWE Systemic Arterial Hypertension treated in the internal medicine outpatient of a school hospital will be included. Adherence to medication will be evaluated using Morisky's 8-item medication adherence scale.
The investigators believe that Pharmaceutical education increases therapeutic adherence in patients with Type 2 Diabetes Mellitus and Systemic Arterial Hypertension.
Patients and study design In this randomized and controlled clinical trial, patients will be assigned to two study groups: intervention group and control group; The patients will be followed for 6 months, considering evaluations at 0, 3 and 6 months.
To improve patient adherence to treatment, the investigators will provide a pocket card with an up-to-date list of the patient's prescribed medications along with recommendations for follow-up care. For the evaluation of adherence to treatment, © MMAS is used, it is authorized: MMAR, LLC., Donald E. Morisky # 6533-7069-1342-3041-5361, 294 Lindura Court, Las Vegas, Nevada 89138-4632.
Variables analyzed After randomization, the investigator will interview patients to obtain demographic data and their medical history. Data such as: time of evolution of the disease, number of prescribed medications, family support, cost of drug treatments will be collected, and the levels of glycosylated hemoglobin, fasting plasma glucose, cholesterol and triglycerides will be determined.
Medication adherence Adherence to medication will be evaluated using the Morisky method of 8 items, which is a validated indicator of non-compliance with medication in the treatment of chronic diseases, the Morisky Medication Adherence Scale It is a generic scale to evaluate the patient's behavior regarding adherence to treatment, the points obtained with MMAS-8 are added to give a range of low, medium and high adherence scores. The total score is a sum of the 8 items and ranges between 0 and 8: values with a score greater than 8 reflect high adherence to medication, values between 6 and 7 reflect medium adherence and values below 6 reflect low adherence.
Sample size calculation A sample size calculation shows that a sample of 38 patients in each group is sufficient to find a difference in adherence to treatment with an alpha error of 0.05 and a power of 0.80 of the test, contemplating a 20% loss. The calculation was performed with the expected proportions formula.
Statistical analysis The investigators will report categorical variables as frequencies and percentages and analyzed with χ2 or Fisher's exact tests as necessary; quantitative variables will be presented as mean and standard deviation. The investigators will use the Wilcoxon test for intragroup comparisons and the Mann-Whitney U test for intergroup comparisons. The results will be considered significant at a two-sided p value of \<0.05, with a 95% confidence interval. The statistical analyzes will be carried out using Statistical Solutions for Products and Services version 24.0.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patients assigned to the intervention group will receive from the research pharmacist, a didactic talk (of at least 10 and up to 20 minutes), where they will be provided information about type 2 diabetes mellitus and Systemic Arterial Hypertension, causes of the disease and consequences of poor control, on its pharmacological treatments, changes in lifestyle and diet. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
Behavioral: pharmaceutical education
Patients assigned to the control group will receive only standard care, represented by regular consultation with their prescribing physician.
The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
Medication adherence
Adherence to medication will be evaluated using the Morisky method of 8 items, which is a valid indicator of non-compliance with medication in the treatment of chronic diseases, the Morisky Medication Adherence Scale is a generic scale to evaluate the behavior of the patient regarding adherence to treatment, the articles obtained with MMAS-8 are added to give a range of low, medium and high adherence scores.
Time frame: Basal
Medication adherence
Adherence to medication will be evaluated using the Morisky method of 8 items, which is a valid indicator of non-compliance with medication in the treatment of chronic diseases, the Morisky Medication Adherence Scale is a generic scale to evaluate the behavior of the patient regarding adherence to treatment, the articles obtained with MMAS-8 are added to give a range of low, medium and high adherence scores.
Time frame: 3 months
Medication adherence
Adherence to medication will be evaluated using the Morisky method of 8 items, which is a valid indicator of non-compliance with medication in the treatment of chronic diseases, the Morisky Medication Adherence Scale is a generic scale to evaluate the behavior of the patient regarding adherence to treatment, the articles obtained with MMAS-8 are added to give a range of low, medium and high adherence scores.
Time frame: 6 months
Plan to share: No
Ran from Jan 2019 to primary completion in Jun 2019, 5 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 5 months is below that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Civil Juan I. Menchaca